What is the clinical evidence from this study?

Study design: Observational. Population: Stable and unstable angina pectoris, acute myocardial infarction. Intervention: Leukocyte counts, MPO, and PAPP-A vs. Healthy controls. Primary outcome: Correct classification of acute coronary events.

What does this research mean for the field?

Combined assessment of leukocyte counts, myeloperoxidase (MPO), and pregnancy-associated plasma protein A (PAPP-A) correctly classifies acute coronary events in 83% of cases. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

January 1, 2010International Journal of Vascular MedicineOpen Access

Leukocyte Counts, Myeloperoxidase, and Pregnancy-Associated Plasma Protein A as Biomarkers for Cardiovascular Disease: Towards a Multi-Biomarker Approach

View Full Paper

Ask AI

Bookmark

Key result

Combining leukocyte counts, MPO, and PAPP-A correctly identifies ~83% of acute coronary events.

Why the study?

The potential of leukocyte counts, MPO, and PAPP-A as combined biomarkers to classify acute coronary events and assess cardiovascular risk was evaluated.

Does a multi-biomarker panel including leukocyte counts, MPO, and PAPP-A correctly classify acute coronary events in patients with angina or MI compared to healthy controls?

Population

Patients with stable and unstable angina pectoris, acute myocardial infarction, and healthy controls

Comparison

Leukocyte counts, CRP, fibrinogen, MPO, and PAPP-A levels vs healthy controls

Design

Observational study

Follow-up

6 months

Authors

MLMarc B. I. LobbesMaastricht University Medical Centre MKM. Eline KooiCardiac Imaging ELEsther LutgensMayo Clinic

Discussion

Member takes

Implication

Biomarker rises in AMI may signal inflammation; leaves open prognostic or therapeutic utility pending larger prospective studies.

Study Design

Type

Observational

Structured PICO

Does a multi-biomarker panel including leukocyte counts, MPO, and PAPP-A correctly classify acute coronary events in patients with angina or MI compared to healthy controls?

Population

Patients with stable and unstable angina pectoris, acute myocardial infarction, and healthy controls, followed for 6 months.

Exposure

Measurement of leukocyte counts, C-reactive protein (CRP), fibrinogen, myeloperoxidase (MPO), and pregnancy-associated plasma protein A (PAPP-A)

Comparator

Healthy controls

Outcome

Classification accuracy for acute coronary events based on biomarker concentrationssurrogate

A multi-biomarker panel of leukocyte counts, MPO, and PAPP-A shows promise for assessing cardiovascular risk by accurately classifying acute coronary events.

Cite This Study

Lobbes et al. (2010) conducted an observational in Stable and unstable angina pectoris, acute myocardial infarction. Leukocyte counts, MPO, and PAPP-A vs. Healthy controls was evaluated on Correct classification of acute coronary events. Combined assessment of leukocyte counts, MPO, and PAPP-A correctly classified study group designation for acute coronary events in 83% of cases.

synapsesocial.com/papers/6ab31f7ebb0f360766b39760 https://doi.org/10.1155/2010/726207

View Full Paper

Ask AI

Bookmark

January 1, 2010International Journal of Vascular MedicineOpen Access

Leukocyte Counts, Myeloperoxidase, and Pregnancy-Associated Plasma Protein A as Biomarkers for Cardiovascular Disease: Towards a Multi-Biomarker Approach

View Full Paper

Ask AI

Bookmark

Key result

Combining leukocyte counts, MPO, and PAPP-A correctly identifies ~83% of acute coronary events.

Why the study?

The potential of leukocyte counts, MPO, and PAPP-A as combined biomarkers to classify acute coronary events and assess cardiovascular risk was evaluated.

Does a multi-biomarker panel including leukocyte counts, MPO, and PAPP-A correctly classify acute coronary events in patients with angina or MI compared to healthy controls?

Population

Patients with stable and unstable angina pectoris, acute myocardial infarction, and healthy controls

Comparison

Leukocyte counts, CRP, fibrinogen, MPO, and PAPP-A levels vs healthy controls

Design

Observational study

Follow-up

6 months

Authors

MLMarc B. I. LobbesMaastricht University Medical Centre MKM. Eline KooiCardiac Imaging ELEsther LutgensMayo Clinic

Discussion

Member takes

Implication

Biomarker rises in AMI may signal inflammation; leaves open prognostic or therapeutic utility pending larger prospective studies.

Study Design

Type

Observational

Structured PICO

Does a multi-biomarker panel including leukocyte counts, MPO, and PAPP-A correctly classify acute coronary events in patients with angina or MI compared to healthy controls?

Population

Patients with stable and unstable angina pectoris, acute myocardial infarction, and healthy controls, followed for 6 months.

Exposure

Measurement of leukocyte counts, C-reactive protein (CRP), fibrinogen, myeloperoxidase (MPO), and pregnancy-associated plasma protein A (PAPP-A)

Comparator

Healthy controls

Outcome

Classification accuracy for acute coronary events based on biomarker concentrationssurrogate

A multi-biomarker panel of leukocyte counts, MPO, and PAPP-A shows promise for assessing cardiovascular risk by accurately classifying acute coronary events.

Cite This Study

synapsesocial.com/papers/6ab31f7ebb0f360766b39760 https://doi.org/10.1155/2010/726207

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark